We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.97B
AUM Growth
-$106M
Cap. Flow
-$271M
Cap. Flow %
-3.88%
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$28.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$26.8M
3
EXAS
Exact Sciences
EXAS
+$15.3M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$13.7M
5
CRL icon
Charles River Laboratories
CRL
+$6.89M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$91.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$38.7M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$24M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Industrials 0.59%
3 Energy 0.02%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
26
Fate Therapeutics
FATE
$324M
$84M 1.2%
3,746,086
+196,000
+6% +$5.66M
SRPT icon
27
Sarepta Therapeutics
SRPT
$1.82B
$83.6M 1.2%
755,898
-383,557
-34% -$38.7M
OPCH icon
28
Option Care Health
OPCH
$3.41B
$82.7M 1.19%
2,629,172
-258,087
-9% -$8.26M
MOH icon
29
Molina Healthcare
MOH
$11.7B
$79.4M 1.14%
240,590
-7,723
-3% -$2.49M
SWAV
30
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$76.8M 1.1%
276,132
-94,567
-26% -$24M
TNDM icon
31
Tandem Diabetes Care
TNDM
$1.17B
$74.9M 1.08%
1,566,015
+250,142
+19% +$13.7M
BDX icon
32
Becton Dickinson
BDX
$43.6B
$74.6M 1.07%
334,838
-8,144
-2% -$2.03M
INSP icon
33
Inspire Medical Systems
INSP
$1.46B
$71.3M 1.02%
401,768
-5,289
-1% -$1.06M
DXCM icon
34
DexCom
DXCM
$29.6B
$69.3M 0.99%
860,460
-68,048
-7% -$5.76M
INSM icon
35
Insmed
INSM
$23.5B
$69.2M 0.99%
3,214,704
-406,858
-11% -$9.75M
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
$68.8M 0.99%
1,007,444
-198,978
-16% -$11.8M
EVH icon
37
Evolent Health
EVH
$654M
$67.2M 0.96%
1,869,055
-149,466
-7% -$5.27M
HUM icon
38
Humana
HUM
$48B
$65.1M 0.93%
134,206
-11,103
-8% -$5.4M
CRSP icon
39
CRISPR Therapeutics
CRSP
$4.71B
$60.7M 0.87%
928,305
+6,300
+0.7% +$457K
AMED
40
DELISTED
Amedisys
AMED
$58M 0.83%
598,934
+13,780
+2% +$1.64M
HCA icon
41
HCA Healthcare
HCA
$82.3B
$52.5M 0.75%
285,789
-6,982
-2% -$1.39M
CI icon
42
Cigna
CI
$74.5B
$52.4M 0.75%
188,701
-4,956
-3% -$1.39M
CRL icon
43
Charles River Laboratories
CRL
$10.8B
$51.8M 0.74%
262,993
+31,924
+14% +$6.89M
CLDX icon
44
Celldex Therapeutics
CLDX
$2.77B
$50.6M 0.73%
1,800,000
+875,000
+95% +$26.8M
MDT icon
45
Medtronic
MDT
$106B
$49.7M 0.71%
615,926
-29,580
-5% -$2.66M
SILK
46
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$47.1M 0.68%
1,047,356
+70
+0% +$3.01K
CDNA icon
47
CareDx
CDNA
$2.05B
$44.3M 0.64%
2,601,446
+63,922
+3% +$1.37M
BIO icon
48
Bio-Rad Laboratories Class A
BIO
$8.15B
$42.5M 0.61%
101,818
+10,657
+12% +$5.31M
EXEL icon
49
Exelixis
EXEL
$14.1B
$41.9M 0.6%
2,673,500
-5,000
-0.2% -$96.6K
CNC icon
50
Centene
CNC
$32.8B
$41.1M 0.59%
528,440
-17,463
-3% -$1.56M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2022 Portfolio in Review

As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.

  • Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
  • Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
  • Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
  • Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
  • Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
  • Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.